Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
AVMXY's Cash to Debt is ranked higher than
92% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 2.75 vs. AVMXY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AVMXY' s Cash to Debt Range Over the Past 10 Years
Min: 18.9  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.78
AVMXY's Equity to Asset is ranked higher than
73% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. AVMXY: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
AVMXY' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.84 Max: 0.96
Current: 0.78
0.51
0.96
Interest Coverage No Debt
AVMXY's Interest Coverage is ranked higher than
89% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 261.39 vs. AVMXY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVMXY' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -5.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -290.58
AVMXY's Operating margin (%) is ranked lower than
86% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. AVMXY: -290.58 )
Ranked among companies with meaningful Operating margin (%) only.
AVMXY' s Operating margin (%) Range Over the Past 10 Years
Min: -1723.37  Med: -288.30 Max: -178.34
Current: -290.58
-1723.37
-178.34
Net-margin (%) -258.44
AVMXY's Net-margin (%) is ranked lower than
85% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. AVMXY: -258.44 )
Ranked among companies with meaningful Net-margin (%) only.
AVMXY' s Net-margin (%) Range Over the Past 10 Years
Min: -1614.68  Med: -242.44 Max: -57.58
Current: -258.44
-1614.68
-57.58
ROE (%) -178.45
AVMXY's ROE (%) is ranked lower than
95% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. AVMXY: -178.45 )
Ranked among companies with meaningful ROE (%) only.
AVMXY' s ROE (%) Range Over the Past 10 Years
Min: -145.87  Med: -86.27 Max: -17.34
Current: -178.45
-145.87
-17.34
ROA (%) -130.32
AVMXY's ROA (%) is ranked lower than
94% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.42 vs. AVMXY: -130.32 )
Ranked among companies with meaningful ROA (%) only.
AVMXY' s ROA (%) Range Over the Past 10 Years
Min: -111.43  Med: -65.83 Max: -13.45
Current: -130.32
-111.43
-13.45
ROC (Joel Greenblatt) (%) -641.76
AVMXY's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. AVMXY: -641.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVMXY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4361.27  Med: -1219.99 Max: -248.87
Current: -641.76
-4361.27
-248.87
EBITDA Growth (3Y)(%) -12.60
AVMXY's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. AVMXY: -12.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AVMXY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -19.40 Max: 26
Current: -12.6
0
26
EPS Growth (3Y)(%) -14.50
AVMXY's EPS Growth (3Y)(%) is ranked lower than
75% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. AVMXY: -14.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AVMXY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.2  Med: -15.50 Max: 29.4
Current: -14.5
-57.2
29.4
» AVMXY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AVMXY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.37
AVMXY's P/B is ranked lower than
99.99% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. AVMXY: 10.37 )
Ranked among companies with meaningful P/B only.
AVMXY' s P/B Range Over the Past 10 Years
Min: 0.28  Med: 1.96 Max: 12
Current: 10.37
0.28
12
P/S 13.28
AVMXY's P/S is ranked lower than
99.99% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. AVMXY: 13.28 )
Ranked among companies with meaningful P/S only.
AVMXY' s P/S Range Over the Past 10 Years
Min: 2  Med: 8.00 Max: 29
Current: 13.28
2
29
Current Ratio 4.33
AVMXY's Current Ratio is ranked higher than
71% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.82 vs. AVMXY: 4.33 )
Ranked among companies with meaningful Current Ratio only.
AVMXY' s Current Ratio Range Over the Past 10 Years
Min: 1.23  Med: 4.92 Max: 126.2
Current: 4.33
1.23
126.2
Quick Ratio 3.85
AVMXY's Quick Ratio is ranked higher than
73% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. AVMXY: 3.85 )
Ranked among companies with meaningful Quick Ratio only.
AVMXY' s Quick Ratio Range Over the Past 10 Years
Min: 1.23  Med: 4.72 Max: 126.2
Current: 3.85
1.23
126.2
Days Inventory 329.87
AVMXY's Days Inventory is ranked lower than
88% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. AVMXY: 329.87 )
Ranked among companies with meaningful Days Inventory only.
AVMXY' s Days Inventory Range Over the Past 10 Years
Min: 101.53  Med: 312.20 Max: 419.94
Current: 329.87
101.53
419.94
Days Sales Outstanding 199.75
AVMXY's Days Sales Outstanding is ranked lower than
91% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 69.24 vs. AVMXY: 199.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVMXY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.69  Med: 179.48 Max: 346.5
Current: 199.75
98.69
346.5
Days Payable 506.65
AVMXY's Days Payable is ranked higher than
98% of the 255 Companies
in the Global Medical Devices industry.

( Industry Median: 60.71 vs. AVMXY: 506.65 )
Ranked among companies with meaningful Days Payable only.
AVMXY' s Days Payable Range Over the Past 10 Years
Min: 112.97  Med: 328.22 Max: 524.05
Current: 506.65
112.97
524.05

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.45
AVMXY's Price/Net Cash is ranked lower than
52% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 12.77 vs. AVMXY: 13.45 )
Ranked among companies with meaningful Price/Net Cash only.
AVMXY' s Price/Net Cash Range Over the Past 10 Years
Min: 1.05  Med: 4.07 Max: 51
Current: 13.45
1.05
51
Price/Net Current Asset Value 4.77
AVMXY's Price/Net Current Asset Value is ranked higher than
62% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 6.29 vs. AVMXY: 4.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AVMXY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1  Med: 4.33 Max: 34
Current: 4.77
1
34
Price/Tangible Book 13.45
AVMXY's Price/Tangible Book is ranked lower than
85% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 4.51 vs. AVMXY: 13.45 )
Ranked among companies with meaningful Price/Tangible Book only.
AVMXY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.47  Med: 2.64 Max: 18.21
Current: 13.45
0.47
18.21
Price/Median PS Value 0.90
AVMXY's Price/Median PS Value is ranked higher than
62% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. AVMXY: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
AVMXY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.58 Max: 15.94
Current: 0.9
0.42
15.94
Earnings Yield (Greenblatt) (%) -15.90
AVMXY's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. AVMXY: -15.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AVMXY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -15.9  Med: 415.20 Max: 83045.2
Current: -15.9
-15.9
83045.2

More Statistics

Revenue(Mil) $2
EPS $ -0.31
Beta-0.02
Short Percentage of Float0.00%
52-Week Range $0.93 - 1.95
Shares Outstanding(Mil)26.64

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:AVH.Australia, GCR.Germany,
Avita Medical Ltd. manufactures & sells regenerative & respiratory medical devices. It offers tissue-engineered products for wound & skin defects, spacers for adolescent & adults, ReCell Spray-On-Skin, Funhaler for asthma & Breath-ATech, among others.
» More Articles for OTCPK:AVMXY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Avita Medical Completes Sale of Respiratory Business for $2.47m Feb 05 2016
Avita Medical Announces Financial Results for Second Quarter Fiscal 2016 Jan 28 2016
Avita Medical CEO Long Term Incentive Plan Jan 25 2016
Avita Medical Appoints Distributors in Japan and South Korea Jan 14 2016
Avita Medical Transforms Board With Three New Appointments Jan 13 2016
Avita Medical Completes Patient Recruitment for Its FDA Approval Study Evaluating Use of ReCell(R)... Jan 11 2016
Avita Medical Sells Respiratory Business for $2.64m Dec 24 2015
FDA Grants ReCell(R) Expedited Access Pathway Designation Dec 14 2015
Avita Medical Highlights Report of 63% Decreased Length of Hospital Stay for Patients With Large... Dec 09 2015
AVITA MEDICAL, LTD. Financials Dec 08 2015
Avita Medical Expands Commercial Reach for ReCell(R) in Wound Care Market With the Appointment of... Nov 24 2015
Avita Medical Ltd. Receives Australian Patent Nov 18 2015
Avita Medical to Present at ARM's 2015 EU Advanced Therapies Investor Day Nov 06 2015
Avita Medical Announces Financial Results and Provides Corporate Update for First Quarter 2016 Oct 28 2015
Avita Medical Presents Research Demonstrating Treatment Power of ReCell(R) in Burns Oct 27 2015
Avita Medical Announces First Patient Treated in US Military Wound Trial Oct 22 2015
Avita Medical Highlights ReCell(R) Findings Published in Journal of Cranio-Maxillo-Facial Surgery Oct 21 2015
Avita Medical Announces AUD$10M Equity Financing Oct 20 2015
Avita Medical Provides Update on ReCell(R) Success in Treating Burn Victims in Taiwan Oct 13 2015
Avita Medical Gains CE Mark for ReGenerCell(R) and ReNovaCell(R) to Complete Skin Healing Portfolio Oct 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK